CA3187734A1 - Chimeric proteins and methods of use for treatment of central nervous system disorders - Google Patents
Chimeric proteins and methods of use for treatment of central nervous system disordersInfo
- Publication number
- CA3187734A1 CA3187734A1 CA3187734A CA3187734A CA3187734A1 CA 3187734 A1 CA3187734 A1 CA 3187734A1 CA 3187734 A CA3187734 A CA 3187734A CA 3187734 A CA3187734 A CA 3187734A CA 3187734 A1 CA3187734 A1 CA 3187734A1
- Authority
- CA
- Canada
- Prior art keywords
- days
- dose
- igf
- variant
- chimeric protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063058888P | 2020-07-30 | 2020-07-30 | |
| US63/058,888 | 2020-07-30 | ||
| PCT/US2021/044019 WO2022026902A2 (en) | 2020-07-30 | 2021-07-30 | Chimeric proteins and methods of use for treatment of central nervous system disorders |
| US17/390,206 US20220031812A1 (en) | 2020-07-30 | 2021-07-30 | Chimeric Proteins and Methods of Use for Treatment of Central Nervous System Disorders |
| US17/390,206 | 2021-07-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3187734A1 true CA3187734A1 (en) | 2022-02-03 |
Family
ID=80002512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3187734A Pending CA3187734A1 (en) | 2020-07-30 | 2021-07-30 | Chimeric proteins and methods of use for treatment of central nervous system disorders |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20220031812A1 (https=) |
| EP (1) | EP4188410B1 (https=) |
| JP (1) | JP2023537318A (https=) |
| CN (1) | CN116917482A (https=) |
| AU (1) | AU2021319203A1 (https=) |
| CA (1) | CA3187734A1 (https=) |
| ES (1) | ES3061325T3 (https=) |
| WO (1) | WO2022026902A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023512423A (ja) | 2019-12-24 | 2023-03-27 | ジュベナ・セラピューティクス・インコーポレイテッド | 再生性ポリペプチドおよびその使用 |
| KR20240029031A (ko) | 2021-06-21 | 2024-03-05 | 쥬베나 테라퓨틱스, 인크. | 재생 폴리펩티드 및 이의 용도 |
| WO2023159067A2 (en) * | 2022-02-15 | 2023-08-24 | Silver Creek Pharmaceuticals, Inc. | Chimeric proteins for treatment of acute radiation syndrome |
| EP4658295A2 (en) * | 2023-02-02 | 2025-12-10 | Silver Creek Pharmaceuticals, Inc. | Methods of treatment using igf-1 chimeric proteins |
| CN116549667B (zh) * | 2023-05-29 | 2024-02-09 | 四川普锐特药业有限公司 | 一种pas修饰的脂质纳米粒、包含其的药物制剂，及其制备方法和用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| JP5577098B2 (ja) * | 2006-12-21 | 2014-08-20 | アムジエン・インコーポレーテツド | ポリペプチドを含有する安定な緩衝化された製剤 |
| ATE502114T1 (de) | 2007-06-21 | 2011-04-15 | Univ Muenchen Tech | Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität |
| CN105524176B (zh) * | 2010-05-21 | 2021-03-19 | 银溪制药股份有限公司 | 双特异性融合蛋白 |
| BR112012029611A2 (pt) | 2010-05-21 | 2017-07-25 | Merrimack Pharmaceuticals Inc | proteína de fusão biespecífica, composição farmacêutica, método de tratamento de dano ao tecido em um indivíduo, método de promoção da regeração ou sobrevivência do tecido em um indivíduo e molécula de ácido nucleico |
| DK2699598T3 (en) * | 2011-04-19 | 2019-04-23 | Pfizer | COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER |
| CN115960249A (zh) | 2015-10-02 | 2023-04-14 | 银溪制药股份有限公司 | 用于组织修复的双特异性治疗性蛋白质 |
-
2021
- 2021-07-30 JP JP2023506330A patent/JP2023537318A/ja active Pending
- 2021-07-30 WO PCT/US2021/044019 patent/WO2022026902A2/en not_active Ceased
- 2021-07-30 ES ES21849618T patent/ES3061325T3/es active Active
- 2021-07-30 US US17/390,206 patent/US20220031812A1/en not_active Abandoned
- 2021-07-30 EP EP21849618.0A patent/EP4188410B1/en active Active
- 2021-07-30 CN CN202180067368.8A patent/CN116917482A/zh active Pending
- 2021-07-30 AU AU2021319203A patent/AU2021319203A1/en active Pending
- 2021-07-30 CA CA3187734A patent/CA3187734A1/en active Pending
-
2025
- 2025-09-08 US US19/321,375 patent/US20260041738A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4188410A2 (en) | 2023-06-07 |
| EP4188410B1 (en) | 2025-11-05 |
| AU2021319203A1 (en) | 2023-03-02 |
| CN116917482A (zh) | 2023-10-20 |
| ES3061325T3 (en) | 2026-04-01 |
| JP2023537318A (ja) | 2023-08-31 |
| US20260041738A1 (en) | 2026-02-12 |
| WO2022026902A2 (en) | 2022-02-03 |
| US20220031812A1 (en) | 2022-02-03 |
| WO2022026902A3 (en) | 2022-03-10 |
| EP4188410A4 (en) | 2024-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20260041738A1 (en) | Chimeric Proteins and Methods of Use for Treatment of Central Nervous System Disorders | |
| JP6401057B2 (ja) | 虚血のための組み合わせ療法 | |
| JP2024113090A (ja) | 神経可塑性を誘導するための方法および組成物 | |
| US20220211808A1 (en) | Haptoglobin for use in treating an adverse secondary neurological outcome following a haemorrhagic stroke | |
| US20240245756A1 (en) | Chimeric proteins and methods of use for treatment of neurodegenerative disorders | |
| JP7118508B2 (ja) | 神経損傷を治療するペプチドベースの方法 | |
| WO2022125548A1 (en) | Growth and differentiation factor 15 for treatment of proliferative vitreoretinopathy therapy | |
| US20250144175A1 (en) | Chimeric proteins for treatment of acute radiation syndrome | |
| CN115942951A (zh) | Ngf变体，制备，组合物和治疗用途 | |
| EP4658295A2 (en) | Methods of treatment using igf-1 chimeric proteins | |
| Zheng et al. | The novel PSD-95 inhibitor BXOS110 provides neuroprotection in acute ischemic stroke | |
| JP2023526507A (ja) | 脳卒中治療のための方法及び組成物 | |
| CN116239701A (zh) | 一种融合蛋白及其应用 | |
| HK40003366B (en) | Combination therapy for ischemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240726 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240726 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250725 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250730 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250730 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250828 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251015 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20251015 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251015 |